Timber Pharmaceuticals Inc. [AMEX: TMBR] stock went on an upward path that rose over 11.70% on Tuesday, amounting to a one-week price increase of more than 24.73%. The company report on January 13, 2021 that Timber Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for TMB-003 for the Treatment of Systemic Sclerosis.
Timber Expects to Submit Investigational New Drug (IND) Application to the FDA in 2022.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
via NewMediaWire — Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TMB-003, the company’s locally delivered formulation of sitaxsentan, for the treatment of systemic sclerosis.
Over the last 12 months, TMBR stock dropped by -80.19%. The average equity rating for TMBR stock is currently 3.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $11.96 million, with 18.89 million shares outstanding and 6.60 million shares in the current float. Compared to the average trading volume of 2.32M shares, TMBR stock reached a trading volume of 25407821 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Timber Pharmaceuticals Inc. [TMBR]:
The Average True Range (ATR) for Timber Pharmaceuticals Inc. is set at 0.13, with the Price to Sales ratio for TMBR stock in the period of the last 12 months amounting to 29.90.
TMBR Stock Performance Analysis:
Timber Pharmaceuticals Inc. [TMBR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 24.73. With this latest performance, TMBR shares dropped by -3.67% in over the last four-week period, additionally sinking by -51.39% over the last 6 months – not to mention a drop of -80.19% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TMBR stock in for the last two-week period is set at 60.90, with the RSI for the last a single of trading hit 69.50, and the three-weeks RSI is set at 56.15 for Timber Pharmaceuticals Inc. [TMBR]. The present Moving Average for the last 50 days of trading for this stock 0.9552, while it was recorded at 0.8984 for the last single week of trading, and 2.0022 for the last 200 days.
Insight into Timber Pharmaceuticals Inc. Fundamentals:
Timber Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.00.
TMBR Stock EPS
With the latest financial reports released by the company, Timber Pharmaceuticals Inc. posted -2.64/share EPS, while the average EPS was predicted by analysts to be reported at -4.02/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 34.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TMBR.
Timber Pharmaceuticals Inc. [TMBR] Insider Position Details
There are presently around $0 million, or 12.30% of TMBR stock, in the hands of institutional investors. The top three institutional holders of TMBR stocks are: BRIDGEWAY CAPITAL MANAGEMENT INC with ownership of 158,300, which is approximately New of the company’s market cap and around 45.20% of the total institutional ownership; SUSQUEHANNA INTERNATIONAL GROUP, LLP, holding 14,759 shares of the stock with an approximate value of $14000.0 in TMBR stocks shares; and VIRTU FINANCIAL LLC, currently with $10000.0 in TMBR stock with ownership of nearly New of the company’s market capitalization.
6 institutional holders increased their position in Timber Pharmaceuticals Inc. [AMEX:TMBR] by around 184,926 shares. Additionally, 5 investors decreased positions by around 58,740 shares, while 1 investors held positions by with 55,091 shares. The mentioned changes placed institutional holdings at 188,575 shares, according to the latest SEC report filing. TMBR stock had 5 new institutional investments in for a total of 184,897 shares, while 4 institutional investors sold positions of 57,678 shares during the same period.